{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:54:22Z","timestamp":1782881662314,"version":"3.54.5"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018375","name":"Fondation FondaMental","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The anticholinergic properties of medications are associated with poorer cognitive performance in schizophrenia. Numerous scales have been developed to assess anticholinergic burden and yet, there is no consensus indicating which anticholinergic burden scale is more relevant for patients with schizophrenia. We aimed to identify valid scales for estimating the risk of iatrogenic cognitive impairment in schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified 27 scales in a literature review. The responses to neuropsychological tests of 839 individuals with schizophrenia or schizoaffective disorder in the FACE-SZ database were collected between 2010 and 2021. We estimated the association between objective global cognitive performance and the 27 scales, the number of psychotropic drugs, and chlorpromazine and lorazepam equivalents in bivariable regressions in a cross-sectional design. We then adjusted the bivariable models with covariates: the predictors significantly associated with cognitive performance in multiple linear regressions were considered to have good concurrent validity to assess cognitive performance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight scales, the number of psychotropic drugs, and drug equivalents were significantly associated with cognitive impairment. The number of psychotropic drugs, the most convenient predictor to compute, was associated with worse executive function (Standardized \u03b2 = \u22120.12, <jats:italic>p<\/jats:italic> = .004) and reasoning (Standardized \u03b2 = \u22120.08, <jats:italic>p<\/jats:italic> = .037).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anticholinergic burden, the number of psychotropic drugs, and drug equivalents were weakly associated with cognition, thus suggesting that cognitive impairment in schizophrenia and schizoaffective disorder is explained by factors other than medication. The number of psychotropic drugs was the most parsimonious method to assess the risk of iatrogenic cognitive impairment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1403093","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T07:52:16Z","timestamp":1718265136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort"],"prefix":"10.3389","volume":"15","author":[{"given":"Nathan","family":"Vidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Urbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristobal","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Capdevielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Clauss-Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romane","family":"Dassing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dubertret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dubreucq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Fond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana-Mihaela","family":"Honciuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Leignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Michel","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Misdrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Pignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Sch\u00fcrhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the FACE-SZ (FondaMental Academic Centers of Expertise\u2014Schizophrenia) Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Passerieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Brunet-Gouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0920-9964(92)90003-n","article-title":"Reliability and validity of a depression rating scale for schizophrenics","volume":"6","author":"Addington","year":"1992","journal-title":"Schizophr. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40266-021-00895-x","article-title":"Quantifying anticholinergic burden and sedative load in older adults with polypharmacy: a systematic review of risk scales and models","volume":"38","author":"Al Rihani","year":"2021","journal-title":"Drugs Aging"},{"key":"B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/JCP.0000000000000790","article-title":"The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia","volume":"37","author":"Ang","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"B5","volume-title":"Doors and people: a test of visual and verbal recall and recognition","author":"Baddeley","year":"2006"},{"key":"B6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.neubiorev.2021.03.028","article-title":"The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: network meta-analyses of randomized controlled trials","volume":"126","author":"Baldez","year":"2021","journal-title":"Neurosci. Biobehav Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1017\/S0033291717003774","article-title":"Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?","volume":"48","author":"Ballesteros","year":"2018","journal-title":"Psychol. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/YCO.0b013e32835d9efb","article-title":"Polypharmacy for schizophrenia","volume":"26","author":"Ballon","year":"2013","journal-title":"Curr. Opin. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/gps.4507","article-title":"Anticholinergic effect on cognition (AEC) of drugs commonly used in older people","volume":"32","author":"Bishara","year":"2017","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/1745509x.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/schbul\/sbm115","article-title":"Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients","volume":"34","author":"Braw","year":"2008","journal-title":"Schizophr. Bull."},{"key":"B12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1017\/s0033291703008900","article-title":"Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs","volume":"34","author":"Br\u00e9bion","year":"2004","journal-title":"Psychol. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.therap.2016.12.010","article-title":"The anticholinergic impregnation scale: towards the elaboration of a scale adapted to prescriptions in French psychiatric settings","volume":"72","author":"Briet","year":"2017","journal-title":"Therapie"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1177\/0091270006292126","article-title":"The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity","volume":"46","author":"Carnahan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1176\/ps.2006.57.8.1094","article-title":"Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial","volume":"57","author":"Chakos","year":"2006","journal-title":"Psychiatr. Serv. Wash DC."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic activity of 107 medications commonly used by older adults","volume":"56","author":"Chew","year":"2008","journal-title":"J. Am. Geriatr. Soc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.psychres.2014.07.067","article-title":"Neurocognition in schizophrenia: from prodrome to multi-episode illness","volume":"220","author":"Corigliano","year":"2014","journal-title":"Psychiatry Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0165-1781(88)90076-5","article-title":"The continuous performance test, identical pairs version (CPT-IP): I. new findings about sustained attention in normal families","volume":"26","author":"Cornblatt","year":"1988","journal-title":"Psychiatry Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.schres.2022.09.014","article-title":"Relapse of first-episode schizophrenia patients and neurocognitive impairment: the role of dopaminergic and anticholinergic burden","volume":"248","author":"Cuesta","year":"2022","journal-title":"Schizophr. Res."},{"key":"B20","volume-title":"CVLT-II: California verbal learning test: adult version","author":"Delis","year":"2000"},{"key":"B21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/2045125314553611","article-title":"Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia","volume":"4","author":"Desmarais","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00228-013-1499-3","article-title":"Systematic review of anticholinergic risk scales in older adults","volume":"69","author":"Dur\u00e1n","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/0269881108100777","article-title":"Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder","volume":"24","author":"\u00c9lie","year":"2010","journal-title":"J. Psychopharmacol. (Oxf)."},{"key":"B24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.schres.2017.03.034","article-title":"Cognitive burden of anticholinergic medications in psychotic disorders","volume":"190","author":"Eum","year":"2017","journal-title":"Schizophr. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eurpsy.2011.02.003","article-title":"The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis","volume":"27","author":"Faber","year":"2012","journal-title":"Eur. Psychiatry J. Assoc. Eur. Psychiatr."},{"key":"B26","volume-title":"Structured clinical Interview for DSM-5 disorders, clinician version (SCID-5-CV)","author":"First","year":"2016"},{"key":"B27","doi-asserted-by":"publisher","first-page":"779607","DOI":"10.3389\/fpsyt.2021.779607","article-title":"Anticholinergic burden and cognitive performance in patients with schizophrenia: a systematic literature review","volume":"12","author":"Georgiou","year":"2021","journal-title":"Front. Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.4088\/jcp.v67n0813","article-title":"Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia","volume":"67","author":"Glick","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"B29","first-page":"231","volume-title":"La batterie GREFEX: donn\u00e9es normatives. Fonctions ex\u00e9cutives et pathologies neurologiques et psychiatriques: \u00c9valuation en pratique clinique","author":"Godefroy","year":"2008"},{"key":"B30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/schbul\/sbr047","article-title":"The relationship between risk of hospitalization for schizophrenia, SES, and cognitive functioning","volume":"37","author":"Goldberg","year":"2011","journal-title":"Schizophr. Bull."},{"key":"B31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","article-title":"Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \u201cright stuff\u201d","volume":"26","author":"Green","year":"2000","journal-title":"Schizophr. Bull."},{"key":"B32","volume-title":"ECDEU assessment manual for psychopharmacology. US department of Health, education, and welfare, public Health service, alcohol, drug abuse, and mental Health administration, national Institute of mental Health, psychopharmacology research branch, division of extramural research programs","author":"Guy","year":"1976"},{"key":"B33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12888-023-04552-y","article-title":"Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia","volume":"23","author":"Haddad","year":"2023","journal-title":"BMC Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/schbul\/sbj011","article-title":"Negative symptoms and cognitive deficits: what is the nature of their relationship?","volume":"32","author":"Harvey","year":"2006","journal-title":"Schizophr. Bull."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.euroneuro.2023.03.001","article-title":"The elephant in the room: medication as confounder","volume":"71","author":"Ilzarbe","year":"2023","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.encep.2021.09.004","article-title":"Anticholinergic scales: use in psychiatry and update of the anticholinergic impregnation scale","volume":"48","author":"Javelot","year":"2022","journal-title":"L\u2019Encephale"},{"key":"B37","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1176\/appi.ajp.2020.20081212","article-title":"Anticholinergic medication burden-associated cognitive impairment in schizophrenia","volume":"178","author":"Joshi","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.schres.2019.01.016","article-title":"Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients","volume":"208","author":"Joshi","year":"2019","journal-title":"Schizophr. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/ggi.13680","article-title":"Development of an anticholinergic burden scale specific for Korean older adults","volume":"19","author":"Jun","year":"2019","journal-title":"Geriatr. Gerontol. Int."},{"key":"B40","unstructured":"Benzodiazepine equivalents conversion calculator\n            KaneS. P.\n          2017"},{"key":"B41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative Syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"B42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","article-title":"The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization","volume":"165","author":"Kern","year":"2008","journal-title":"Am. J. Psychiatry."},{"key":"B43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12877-018-0929-6","article-title":"An anticholinergic burden score for German prescribers: score development","volume":"18","author":"Kiesel","year":"2018","journal-title":"BMC Geriatr."},{"key":"B44","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1600-0447.2012.01835.x","article-title":"Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment","volume":"125","author":"L\u00e4ngle","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/schbul\/sbv037","article-title":"Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophr. Bull."},{"key":"B46","volume-title":"Neuropsychological assessment","author":"Lezak","year":"2004"},{"key":"B47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00228-020-02994-x","article-title":"Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review","volume":"77","author":"Lisibach","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/bcpt.13692","article-title":"High anticholinergic burden at admission associated with in-hospital mortality in older patients: a comparison of 19 different anticholinergic burden scales","volume":"130","author":"Lisibach","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2288-10-112","article-title":"Comparison of imputation methods for handling missing covariate data when fitting a Cox proportional hazards model: a resampling study","volume":"10","author":"Marshall","year":"2010","journal-title":"BMC Med. Res. Methodol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and memory in schizophrenia","volume":"161","author":"Minzenberg","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1017\/S1461145713000837","article-title":"History, background, concepts and current use of comedication and polypharmacy in psychiatry","volume":"17","author":"M\u00f6ller","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12982-017-0062-6","article-title":"Model checking in multiple imputation: an overview and case study","volume":"14","author":"Nguyen","year":"2017","journal-title":"Emerg. Themes Epidemiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1176\/ps.2009.60.2.210","article-title":"Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients","volume":"60","author":"Olfson","year":"2009","journal-title":"Psychiatr. Serv. Wash DC."},{"key":"B54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.scog.2018.10.001","article-title":"From \u201cunder\u201d to \u201cover\u201d social cognition in schizophrenia: is there distinct profiles of impairments according to negative and positive symptoms?","volume":"15","author":"Peyroux","year":"2019","journal-title":"Schizophr. Res. Cogn."},{"key":"B55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12991-015-0042-6","article-title":"Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders","volume":"14","author":"Pinna","year":"2015","journal-title":"Ann. Gen. Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1176\/appi.psy.43.1.31","article-title":"Tricyclic antidepressants and cognitive decline","volume":"43","author":"Podewils","year":"2002","journal-title":"Psychosomatics"},{"key":"B57","volume-title":"Adaptation en langue fran\u00e7aise du California Verbal Learning TestParis Ed. Cent. Psychol. Appliqu\u00e9e","author":"Poitrenaud","year":"2007"},{"key":"B58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/jpm12020207","article-title":"CRIDECO anticholinergic load scale: an updated anticholinergic burden scale. Comparison with the ACB scale in Spanish individuals with subjective memory complaints","volume":"12","author":"Ramos","year":"2022","journal-title":"J. Pers. Med."},{"key":"B59","first-page":"271","volume-title":"Validity of the Trail Making Test as an indicator of organic brain damage","author":"Reitan","year":"1958"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1592\/phco.2005.25.11.1592","article-title":"Methods for assessing drug-related anticholinergic activity","volume":"25","author":"Rudd","year":"2005","journal-title":"Pharmacotherapy"},{"key":"B61","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","article-title":"The anticholinergic risk scale and anticholinergic adverse effects in older persons","volume":"168","author":"Rudolph","year":"2008","journal-title":"Arch. Intern Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12877-015-0029-9","article-title":"Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review","volume":"15","author":"Salahudeen","year":"2015","journal-title":"BMC Geriatr."},{"key":"B63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/WNF.0000000000000442","article-title":"Long-term benzodiazepine prescription during maintenance therapy of individuals with psychosis spectrum disorders-associations with cognition and global functioning","volume":"44","author":"Savi\u0107","year":"2021","journal-title":"Clin. Neuropharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.schres.2013.07.009","article-title":"The global cognitive impairment in schizophrenia: consistent over decades and around the world","volume":"150","author":"Schaefer","year":"2013","journal-title":"Schizophr. Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000325171","article-title":"Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study","volume":"31","author":"Sittironnarit","year":"2011","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"Van Buuren","year":"2011","journal-title":"J. Stat. Softw."},{"key":"B67","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.schres.2009.03.035","article-title":"Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis","volume":"113","author":"Ventura","year":"2009","journal-title":"Schizophr. Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1017\/S0033291720001403","article-title":"Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers","volume":"51","author":"Verdoux","year":"2021","journal-title":"Psychol. Med."},{"key":"B69","unstructured":"Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort\n            VidalN.\n            RouxP.\n            UrbachM.\n            BelmonteC.\n            BoyerL.\n            CapdevielleD.\n          2024"},{"key":"B70","volume-title":"WAIS-III, Wechsler adult intelligence scale: administration and scoring manual","author":"Wechsler","year":"1997"},{"key":"B71","volume-title":"WAIS-IV: Wechsler adult intelligence scale","author":"Wechsler","year":"2008"},{"key":"B72","first-page":"239","volume-title":"Behavioural assessment of the dysexecutive syndrome","author":"Wilson","year":"1997"},{"key":"B73","first-page":"110","article-title":"A test battery for attentional performance","volume-title":"Applied neuropsychology of attention","author":"Zimmermann","year":"2002"},{"key":"B74","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/YCO.0b013e3283366427","article-title":"Polypharmacy in schizophrenia","volume":"23","author":"Zink","year":"2010","journal-title":"Curr. Opin. Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1403093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T07:52:27Z","timestamp":1718265147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1403093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":74,"alternative-id":["10.3389\/fphar.2024.1403093"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1403093","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"article-number":"1403093"}}